Practice of adjunctive treatments in critically ill COVID–19 patients—rational for the multicenter observational PRoAcT-COVID study in The Netherlands
Frederique Paulus(Amsterdam University Medical Centers), Janneke Horn(Amsterdam University Medical Centers), Pien Swart(Amsterdam University Medical Centers), Willemke Stilma(OLVG), Marcus J. Schultz(University of St.Gallen), Marcelo Gama de Abreu(Cleveland Clinic), Sheila Nainan Myatra(Homi Bhabha National Institute), Ward H. van der Ven(The University of Melbourne), Ignacio Martín‐Loeches(St. James's Hospital), Ary Serpa Neto(The University of Melbourne), Sunny G. L. H. Nijbroek(Amsterdam University Medical Centers), Lieuwe D. J. Bos(Amsterdam Neuroscience), Christel M. A. Valk(Amsterdam Neuroscience), Neeltje M. Rosenberg(GGD Amsterdam), L.S. Boers(Amsterdam UMC Location University of Amsterdam), Michela Botta(Amsterdam University Medical Centers), Markus W. Hollmann(European Society of Anaesthesiology), Guido Mazzinari(Universitat de València), Liselotte Hol(Apple (Israel)), Anissa M. Tsonas(Amsterdam UMC Location University of Amsterdam)
Cited by 10
Related Papers
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies
|Intensive Care Medicine|2023|855